Development of Cobinamide as a Novel Treatment for Aortic Aneurysms of Marfan Syndrome: Phase I Pharmacokinetic Studies

Cobinamide 作为马凡综合征主动脉瘤的新型治疗方法的开发:I 期药代动力学研究

基本信息

  • 批准号:
    10545967
  • 负责人:
  • 金额:
    $ 31.14万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-08-01 至 2024-07-31
  • 项目状态:
    已结题

项目摘要

Marfan Syndrome (MFS) is a genetic disorder, with a prevalence of ~ 1 in 5,000 people. Aneurysms in the ascending aorta are the most serious manifestation of the disease and can lead to sudden death due to spontaneous rupture. Existing treatments are marginally effective. The aneurysms are due largely to increased oxidative stress in aortic smooth muscle cells from abnormal production of superoxide anion and nitric oxide. Cobinamide is the penultimate precursor in the biosynthesis of cobalamin (vitamin B12) and is a powerful antioxidant, serving as a superoxide dismutase and catalase mimetic and neutralizing nitric oxide and peroxynitrite. We have found that administering cobinamide in the drinking water to mice with a fibrillin-1 mutation analogous to a common mutation in Marfan patients abolished oxidative stress and pathological changes in the aorta, and significantly reduced aortic dilation. Our goal is to develop cobinamide as a novel, disease-modifying treatment that could be used in patients with MFS and other forms of aortic aneurysms associated with oxidative stress. An international patent has been submitted for using cobinamide to treat aortic aneurysms, and Dr. Boss, co-investigator on this application, holds patents for using cobinamide as an antidote against toxic chemicals. In this Phase I SBIR grant, we propose to perform pharmacokinetic (PK) studies in rats after oral administration of cobinamide (Aim I) and to synthesize sufficient non-GMP grade cobinamide for the PK studies (Aim II). We propose four interrelated studies in Aim I. (A) Dose Determination Studies. We will determine the single dose administered by gavage required to achieve the plasma concentration found after administering cobinamide continuously in drinking water to mice. (B) Formulation Selection and Mode of Administration Studies. We will compare four different cobinamide formulations, using the dose found in Aim 1A. We will compare the PK profile between administering the drug by gavage to direct instillation into the duodenum in cannulated rats, since gastric acidity could affect cobinamide absorption. The goal is to find the formulation and administration mode that yield the highest plasma concentration for the longest time. (C) Bioavailability Studies. We will use the optimal formulation and administration mode found in Aim 1B and compare the PK profile to that found after injecting the drug intravenously. (D) Repeated Dose Studies. Using the formulation and administration mode found best in Aim 1B, we will determine the frequency of administration required to maintain a steady-state, target plasma concentration. A subsequent Phase II SBIR grant would consist of synthesizing and formulating GMP-grade cobinamide, and performing GLP-level PK and toxicology studies in rats and pigs. The SBIR studies would complement and be performed simultaneously with efficacy and basic mechanistic studies supported by a five-year R01 grant expected to start 04/01/22. Technical and business assistance is requested to develop a high-level plan describing activities that would lead to FDA approval and commercialization of cobinamide.
马凡综合征(MFS)是一种遗传性疾病,患病率为每5000人中有1人。脑部的动脉瘤 升主动脉是该病最严重的表现,可因以下原因导致猝死 自发性破裂。现有的治疗方法略微有效。动脉瘤在很大程度上是由于 超氧阴离子和一氧化氮异常产生引起的主动脉平滑肌细胞氧化应激。 钴酰胺是钴胺(维生素B12)生物合成的倒数第二个前体,是一种强大的 抗氧化剂,作为一种超氧化物歧化酶和过氧化氢酶模拟和中和一氧化氮和 过氧亚硝酸盐。我们已经发现,在饮用水中给予携带纤维蛋白-1突变的小鼠可比胺 类似于马凡患者的一种常见突变,消除了氧化应激和细胞的病理变化 并显著降低了主动脉的扩张。我们的目标是开发可比胺作为一种新型的疾病改良剂 可用于MFS和其他形式的与氧化相关的主动脉瘤患者的治疗 压力。一项使用可比胺治疗主动脉瘤的国际专利已经提交,博斯博士, 这项申请的联合研究员,拥有将可比酰胺用作有毒化学物质解毒剂的专利。 在这一阶段的SBIR赠款中,我们建议在大鼠口服后进行药代动力学(PK)研究 给药(目标I)并为PK研究合成足够的非GMP级的可比酰胺 (目标II)。我们在AIM I(A)剂量决定研究中提出了四项相互关联的研究。我们将确定 单次灌胃给药需要达到给药后的血药浓度 连续给小鼠饮水中的可比胺。(B)提法选择和管理方式 研究。我们将使用目标1A中发现的剂量来比较四种不同的可比胺配方。我们会 大鼠十二指肠直接滴注与灌胃给药的PK谱比较 去势大鼠,因为胃酸会影响可比胺的吸收。我们的目标是找到公式和 最长时间内产生最高血药浓度的给药模式。(C)生物利用度研究。 我们将使用目标1B中找到的最佳配方和管理模式,并将PK配置文件与 在静脉注射毒品后发现的。(D)重复剂量研究。使用该配方和 在目标1B中找到最好的管理模式,我们将确定需要维持的管理频率 一个稳定状态的目标血浆浓度。 随后的第二阶段SBIR赠款将包括合成和配制GMP级可比酰胺, 并在大鼠和猪身上进行GLP水平的PK和毒理学研究。SBIR研究将补充和 与药效研究和基础机制研究同时进行,由五年期R01拨款支持 预计从04/01/22开始。要求技术和商业援助以制定一项高级别计划 描述将导致FDA批准可比胺并将其商业化的活动。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Kenneth Dretchen其他文献

Kenneth Dretchen的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

相似海外基金

Understanding the Impacts of Lewis Acidity and Coordination on Butyl Rubber Polymerization
了解路易斯酸度和配位对丁基橡胶聚合的影响
  • 批准号:
    575175-2022
  • 财政年份:
    2022
  • 资助金额:
    $ 31.14万
  • 项目类别:
    Alliance Grants
New Concepts in Lewis Acidity, Catalysis, and Polymer Science: Functional Main Group Cages
路易斯酸、催化和高分子科学的新概念:功能主族笼
  • 批准号:
    RGPIN-2018-05574
  • 财政年份:
    2022
  • 资助金额:
    $ 31.14万
  • 项目类别:
    Discovery Grants Program - Individual
Constraining the Sulphur Cycling Pathway Causing Delayed Acidity in Mine Wastewater
限制硫循环路径导致矿山废水酸度延迟
  • 批准号:
    568873-2022
  • 财政年份:
    2022
  • 资助金额:
    $ 31.14万
  • 项目类别:
    Postgraduate Scholarships - Doctoral
Quantifying Lewis acidity for Chemoselective Lewis acid Catalysis
化学选择性路易斯酸催化中路易斯酸度的定量
  • 批准号:
    559925-2021
  • 财政年份:
    2022
  • 资助金额:
    $ 31.14万
  • 项目类别:
    Alexander Graham Bell Canada Graduate Scholarships - Doctoral
Control of Inflammatory Acidity in Mucosal Inflammation
粘膜炎症中炎症酸度的控制
  • 批准号:
    10512056
  • 财政年份:
    2021
  • 资助金额:
    $ 31.14万
  • 项目类别:
New Concepts in Lewis Acidity, Catalysis, and Polymer Science: Functional Main Group Cages
路易斯酸、催化和高分子科学的新概念:功能主族笼
  • 批准号:
    RGPIN-2018-05574
  • 财政年份:
    2021
  • 资助金额:
    $ 31.14万
  • 项目类别:
    Discovery Grants Program - Individual
CAREER: Permissive acidity as a regulator of plant cell expansion
职业:允许的酸度作为植物细胞扩张的调节剂
  • 批准号:
    2045795
  • 财政年份:
    2021
  • 资助金额:
    $ 31.14万
  • 项目类别:
    Standard Grant
Elucidation of rhizospheric consortium responses to two gradients of climate and soil acidity
阐明根际群落对气候和土壤酸度两个梯度的响应
  • 批准号:
    21H02232
  • 财政年份:
    2021
  • 资助金额:
    $ 31.14万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Control of Inflammatory Acidity in Mucosal Inflammation
粘膜炎症中炎症酸度的控制
  • 批准号:
    10255086
  • 财政年份:
    2021
  • 资助金额:
    $ 31.14万
  • 项目类别:
Quantifying Lewis acidity for Chemoselective Lewis acid Catalysis
化学选择性路易斯酸催化中路易斯酸度的定量
  • 批准号:
    559925-2021
  • 财政年份:
    2021
  • 资助金额:
    $ 31.14万
  • 项目类别:
    Alexander Graham Bell Canada Graduate Scholarships - Doctoral
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了